Rethinking Muscle Health Assessment in GLP ‐1–Based Therapies for Obesity: Beyond Lean Mass

Diabetes Obesity and Metabolism 2026

View at publisher
Authors: Mojca Jensterle, Andrej Janež
DOI: 10.1111/dom.70649
Cited by: 4
References: 22

Abstract

M.J. reports receiving lecture honoraria from Novo Nordisk, Eli Lilly, Pfeizer, Amgen, AstraZeneca, Novartis and Sanofi and being an advisory board member of Novo Nordisk, Eli Lilly, Amgen and Pfeizer. A.J. has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Abbott, Novo Nordisk, Medtronic, and Sanofi. The data that support the findings of this study are available from the corresponding author upon reasonable request. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70649.

Fields of Study & Subjects

Diabetes Treatment and Management Regulation of Appetite and Obesity Metabolism Diabetes and Cancer

Publication details

Journal / source
Diabetes Obesity and Metabolism
Publisher
Wiley
Volume
28
Issue
6
Pages
4428–4431
Publication date
10 March 2026
Language
EN